how dantrolene might be used to treat spasticity
Dantrolene is believed to act primarily in the peripheral nervous system rather than centrally through a direct effect on muscle contraction. Clinical trials have suggested its benefit in reducing spasticity associated with cerebrovascular accidents, spinal cord injury, multiple sclerosis, and cerebral palsy. It may be hepatotoxic and therefore needs to be carefully monitored, especially in older patients. It has been reported to cause generalized weakness in some patients. Therapy is initiated with one 25 mg tablet daily. Benefits should be noted within 4 to 6 weeks.